Methadone for Opioid Use Disorder

This trial investigates a new method for restarting methadone treatment in individuals with opioid use disorder (OUD), particularly those using fentanyl. The study examines whether restarting methadone at a higher dose is safe and effective for those who have missed several doses, compared to the standard gradual increase. This approach may benefit individuals who were stable on methadone but missed 4-8 doses and increased fentanyl use after stopping. Potential participants should have a history of methadone treatment and increased fentanyl use after missing doses, without recent overdose or heart issues. As a Phase 4 trial, this study involves an FDA-approved treatment and aims to understand its benefits for a broader patient population.

The trial does not specify if you need to stop taking your current medications, but you cannot have used buprenorphine-naloxone (Suboxone®, Sublocade®, Butrans®) within the previous 3 days.

Research has shown that quickly restarting methadone treatment is generally safe for people with opioid use disorder. Studies have found that methadone is well-tolerated, even at higher doses. For instance, rapidly adjusting the methadone dose allowed patients to safely reach higher levels without serious side effects. Notably, over 80% of patients continued their treatment after this rapid process, indicating its manageability for most people.

One study found that starting methadone at 60 mg on the first day and increasing to about 100 mg by the end of the first week was safe. This method proved effective even for those who had used fentanyl, a strong opioid. Methadone can reduce the risk of death by 50% for people with opioid use disorder.

Researchers are excited about the Methadone rapid restart protocol because it addresses the challenge of missed doses in opioid use disorder treatment. Unlike traditional methods that require a cautious, gradual increase back to the maintenance dose after missed doses, this approach allows for a quicker return to the previous stable dose or a safe lower dose. This could potentially reduce withdrawal symptoms and the risk of relapse, offering a more flexible and patient-friendly option for those on methadone maintenance or titration. By focusing on a rapid re-initiation, the protocol aims to enhance treatment adherence and overall success in managing opioid use disorder.

Studies have shown that methadone effectively treats opioid use disorder (OUD), reducing the risk of death by 50% for those in treatment. Higher doses, typically between 60-120mg per day, help people remain in treatment longer and enhance its effectiveness. For individuals using fentanyl, who may have a higher tolerance, research indicates that methadone remains effective, though dose adjustments might be necessary. Methadone generally helps more people stay in treatment compared to options like buprenorphine. In this trial, the rapid restart approach for methadone aims to quickly return patients to their previous stable doses. Participants on methadone maintenance treatment will resume 100% of their most recent dose, while those being titrated will restart on the lower of their two most recent dosages. Early clinical experiences suggest this approach could benefit those with high opioid tolerance.¹³⁶⁷⁸